These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31166030)

  • 1. FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?
    Milunović V; Mišura Jakobac K; Kursar M; Mandac Rogulj I; Ostojić Kolonić S
    Eur J Haematol; 2019 Sep; 103(3):145-151. PubMed ID: 31166030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
    Nikolaenko L; Nademanee A
    Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
    Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
    Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma.
    Choi Y; Diefenbach CS
    Expert Rev Hematol; 2019 Oct; 12(10):801-808. PubMed ID: 31432732
    [No Abstract]   [Full Text] [Related]  

  • 5. [Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].
    Calleja A; Bouclet F
    Bull Cancer; 2021 Jan; 108(1):12-13. PubMed ID: 33308986
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience.
    Nanni L; Pellegrini C; Stefoni V; Argnani L; Cavo M; Zinzani PL
    Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e595-e596. PubMed ID: 31543370
    [No Abstract]   [Full Text] [Related]  

  • 8. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
    Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
    Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
    Gibb A; Pirrie SJ; Linton K; Warbey V; Paterson K; Davies AJ; Collins GP; Menne T; McKay P; Fields PA; Miall FM; Nagy E; Wheatley K; Reed R; Baricevic-Jones I; Barrington S; Radford J
    Br J Haematol; 2021 Apr; 193(1):63-71. PubMed ID: 32926420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
    Kumar A; Casulo C; Advani RH; Budde E; Barr PM; Batlevi CL; Caron P; Constine LS; Dandapani SV; Drill E; Drullinsky P; Friedberg JW; Grieve C; Hamilton A; Hamlin PA; Hoppe RT; Horwitz SM; Joseph A; Khan N; Laraque L; Matasar MJ; Moskowitz AJ; Noy A; Palomba ML; Schöder H; Straus DJ; Vemuri S; Yang J; Younes A; Zelenetz AD; Yahalom J; Moskowitz CH
    J Clin Oncol; 2021 Jul; 39(20):2257-2265. PubMed ID: 33909449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.
    Metzger ML; Link MP; Billett AL; Flerlage J; Lucas JT; Mandrell BN; Ehrhardt MJ; Bhakta N; Yock TI; Friedmann AM; de Alarcon P; Luna-Fineman S; Larsen E; Kaste SC; Shulkin B; Lu Z; Li C; Hiniker SM; Donaldson SS; Hudson MM; Krasin MJ
    J Clin Oncol; 2021 Jul; 39(20):2276-2283. PubMed ID: 33826362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising new second-line therapy for Hodgkin lymphoma.
    Gourd E
    Lancet Oncol; 2019 Feb; 20(2):e76. PubMed ID: 30686705
    [No Abstract]   [Full Text] [Related]  

  • 13. Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.
    Suri A; Mould DR; Song G; Collins GP; Endres CJ; Gomez-Navarro J; Venkatakrishnan K
    Clin Pharmacol Ther; 2019 Dec; 106(6):1268-1279. PubMed ID: 31152605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin as consolidation after hematopoietic cell transplant for relapsed Hodgkin lymphoma in pediatric patients.
    Flerlage JE; von Buttlar X; Krasin M; Triplett B; Kaste SC; Metzger ML
    Pediatr Blood Cancer; 2019 Dec; 66(12):e27962. PubMed ID: 31429511
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
    Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM
    Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brentuximab vedotin monotherapy is an effective treatment in a frail pediatric patient with Down syndrome and classical Hodgkin lymphoma.
    Vonasek J; Edslev PW; d'Amore F; Hasle H
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28082. PubMed ID: 31724794
    [No Abstract]   [Full Text] [Related]  

  • 18. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan.
    Tien FM; Tsai CH; Liu JH; Lin CT
    J Formos Med Assoc; 2019 Oct; 118(10):1466-1470. PubMed ID: 31337522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Remission by Brentuximab Vedotin for Non-mediastinal Gray Zone Lymphoma Refractory to Autologous Stem Cell Transplantation.
    Ebisawa K; Masamoto Y; Koya J; Shimura A; Shinozaki-Ushiku A; Toyama K; Nakazaki K; Kurokawa M
    Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e602-e604. PubMed ID: 31551171
    [No Abstract]   [Full Text] [Related]  

  • 20. The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
    McMillan A; O'Neill AT; Townsend W; Lambert J; Virchis A; Shah R; Menezes L; Humphries P; Von Both K; Grandage V; Carpenter B; Hough R; Ardeshna KM; Daw S
    Br J Haematol; 2021 Feb; 192(3):e84-e87. PubMed ID: 33426648
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.